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TB is short for tuberculosis. TB 
disease is caused by a bacterium called 
Mycobacterium tuberculosis. The bacteria 
usually attack the lungs, but TB bacteria 
can attack any part of the body. If not 
treated properly, TB disease can be fatal. 
TB is spread through the air from one 
person to another when a person with 
active TB disease of the lungs or throat 
coughs, sneezes, speaks, or sings. People 
nearby may breathe in these bacteria and 
become infected.
TB bacteria can live in the body without 
making a person sick. This is called latent 
TB infection (LTBI). In most people who 
breathe in TB bacteria and become infected, 
the body is able to fight the bacteria to 
stop it from growing. People with latent 
TB infection do not feel sick and do not 
have any symptoms. TB bacteria become 
active if the immune system can’t stop it 
from growing. When TB bacteria are active 
(multiplying in the body), this is called 
active TB disease.
TB is particularly dangerous for people with 
HIV infection. People who have both HIV 
infection and LTBI are 20 to 30 times as 
likely to develop active TB disease as those 
who do not have HIV infection. Worldwide, 
TB is the leading cause of death among 
persons with HIV infection and almost 
one in four deaths among people with HIV 
infection is due to TB. In 2007, there were 
554 deaths due to TB in the United States 
(US), continuing a long-standing decline in 
TB deaths since the early 1950s.
The only sign of TB infection is a positive 
reaction to the tuberculin skin test or 
special TB blood test. All persons newly 
diagnosed with HIV infection should 
be tested for TB as soon as possible and 
people living with HIV and at risk for  
TB exposure should be tested annually  
to find out if they have LTBI. Persons 
with LTBI need treatment (most 
commonly isoniazid) as soon as possible 
to prevent them from developing active 
TB disease. Persons with active TB 
disease must take prescribed medication 
to treat the infection.




• Approximately 1.1 million persons were 
living with HIV infection at the end of 
2006. As many as 21% of infected persons 
are unaware of their infection. 
• It is estimated that about 4.2% of 
Americans with or without HIV infection 
are infected with the TB bacteria. That 
means in 2009 there were approximately 
13 million Americans with LTBI. 
• In 2009, among persons with TB who had a 
documented HIV test result, more than 10% 
(690 of 6,743) were co-infected with HIV.
• In 2005, of the TB patients reported  
to be co-infected with HIV, 63% were  
non-Hispanic blacks.
• In 2006, the HIV status of 1 in 5 patients 
with TB was not known, even though 
CDC recommends that all persons with 
TB be tested for HIV. 
• In 2006, nearly 20% of patients with TB 
and HIV died. Persons with HIV and TB 
accounted for 32% of those who died 
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www.cdc.gov/hiv 
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Prevention Challenges
Multidrug Resistance to TB
Multidrug-resistant TB (MDR TB)  
is TB that is resistant to at least two of 
the best anti-TB drugs—isoniazid and 
rifampin. MDR TB is extremely difficult 
to treat and can be fatal. Every nation 
must face the challenge of combating 
MDR TB. People with HIV infection 
are at greater risk of dying of MDR TB. 
Although the percentage of MDR TB 
cases in the United States has remained 
steady since 1998, MDR TB has now 
been reported in nearly all states and  
the District of Columbia. In 2009,  
1.2% of reported TB cases were 
multidrug resistant.
To prevent the continued emergence of 
drug-resistant strains of TB, treatment 
for TB must be improved, not only in the 
US but worldwide. Inconsistent or partial 
treatment is a main cause of MDR TB. 
The most effective strategy for ensuring 
the completion of treatment is directly 
observed therapy (DOT), and its use 
must be expanded. In DOT a health care 
worker meets with a person who has TB 
and watches them take each dose of  
TB medication.
Treatment Interactions 
Recommendations for treating 
tuberculosis in adults with HIV  
infection are, with a few exceptions, 
the same as those for adult TB patients 
who are not HIV infected. However, 
managing HIV-related TB is complex 
and people with HIV and TB should 
seek care from a health care provider 
or providers with expertise in the 
management of both HIV disease and 
TB. Because persons with HIV infection 
are often taking numerous medications, 
some of which interact with anti-TB 
medications, experts in the treatment of 
HIV-related TB should be consulted.
What CDC Is Doing
CDC and its domestic and international 
partners, including the National TB 
Controllers Association, Stop TB USA, 
and the global Stop TB Partnership, are 
taking many steps to prevent further 
spread of TB and to reduce the overall 
burden of the disease. Efforts include
• assessing new TB diagnostic 
techniques, 
• developing new treatment regimens 
and increasing the capacity of health 
professionals to provide adequate 
treatment, and 
• issuing new recommendations for 
improved testing and treatment for  
US immigrants. 
A new rapid diagnostic test for TB 
disease, the Xpert MTB/RIF assay 
(which is not currently approved by 
the US Food and Drug Administration 
for use in the US, is expected to reduce 
patient and health service diagnostic 
delays, decentralize the diagnosis of 
MDR TB and HIV-associated TB, and 
accelerate patient access to appropriate 
care. Evidence suggests that use of the 
test might double the number of HIV-
associated TB cases diagnosed in areas 
with high rates of TB and HIV. 
TB control is an exercise in vigilance. 
The goal of controlling and eventually 
eliminating TB worldwide requires 
a focused, continual effort to address 
the prevention and treatment needs of 
persons most at risk, including those 
who have HIV infection. Preventing 
and treating TB in persons with HIV 
infection are therefore essential to 
achieving the goal of TB elimination 
both in the US and globally.
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